The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Dinesh C. Paliwal net worth and biography

Dinesh Paliwal Biography and Net Worth

Director of Bristol-Myers Squibb

Mr. Paliwal has served as Chairman, President and Chief Executive Officer of Harman International Industries, Inc., the connected technologies company for automotive, consumer and enterprise markets, since July 2008. Mr. Paliwal has served as President and Chief Executive Officer of Harman since July 2007.Prior to joining Harman, Mr. Paliwal served as a member of the Group Executive Committee of ABB Ltd., a provider of industrial automation, power transmission systems and services, from January 2001 until June 2007.Mr. Paliwal also served as President of Global Markets and Technology of ABB Ltd. from January 2006 until June 2007, as Chairman and Chief Executive Officer of ABB North America from January 2004 until June 2007, and as President and Chief Executive Officer of ABB Automation Technologies Division from October 2002 to December 2005.Mr. Paliwal serves on the board of the Business Advisory Council of the Farmer School of Business, Miami University and the U.S. India Business Council (USIBC) board of directors. He also is a member of the CEO Business Roundtable in Washington, D.C., and the U.S. India CEO Forum.

What is Dinesh C. Paliwal's net worth?: The estimated net worth of Dinesh C. Paliwal is at least $1.24 million as of June 15th, 2020. Mr. Paliwal owns 22,109 shares of Bristol-Myers Squibb stock worth more than $1,239,431 as of December 30th. This net worth approximation does not reflect any other assets that Mr. Paliwal may own. Learn More about Dinesh C. Paliwal's net worth.
How do I contact Dinesh C. Paliwal?: The corporate mailing address for Mr. Paliwal and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Dinesh C. Paliwal's contact information.
Has Dinesh C. Paliwal been buying or selling shares of Bristol-Myers Squibb?: Dinesh C. Paliwal has not been actively trading shares of Bristol-Myers Squibb during the past quarter. Most recently, on Monday, June 15th, Dinesh C. Paliwal bought 9,174 shares of Bristol-Myers Squibb stock. The stock was acquired at an average cost of $54.50 per share, with a total value of $499,983.00. Following the completion of the transaction, the director now directly owns 22,109 shares of the company's stock, valued at $1,204,940.50. Learn More on Dinesh C. Paliwal's trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Samit Hirawat (EVP, Chief Medical Officer and Head of Development), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 1 times. They purchased a total of 1,830 shares worth more than $100,046.10. During the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 700 shares worth more than $38,934.00. The most recent insider tranaction occured on November, 4th when SVP Phil M Holzer sold 700 shares worth more than $38,934.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 11/4/2024.

Dinesh C. Paliwal Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/15/2020	Buy	9,174	$54.50	$499,983.00	22,109
4/30/2018	Buy	4,770	$52.40	$249,948.00	8,027

Dinesh C. Paliwal Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $56.06

$56.05

$57.60

50 Day Range

MA: $56.82

$51.92

$59.94

2 Week Range

Now: $56.06

$39.35

$61.08

Volume

6,589,592 shs

Average Volume

14,026,268 shs

Market Capitalization

$113.70 billion

P/E Ratio

N/A

Dividend Yield

4.14%

Beta

0.45

Vladimir Lenin was right…

From Porter & Company | Ad